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Hypertension is a common disorder with uncertain etiology. In the last several years, it has
become evident that components of both the innate and adaptive immune system play
an essential role in hypertension. Macrophages andT cells accumulate in the perivascular
fat, the heart and the kidney of hypertensive patients, and in animals with experimental
hypertension. Various immunosuppressive agents lower blood pressure and prevent end-
organ damage.Mice lacking lymphocytes are protected against hypertension, and adoptive
transfer of T cells, but not B cells in the animals restores their blood pressure response
to stimuli such as angiotensin II or high salt. Recent studies have shown that mice lack-
ing macrophages have blunted hypertension in response to angiotensin II and that genetic
deletion ofmacrophagesmarkedly reduces experimental hypertension. Dendritic cells have
also been implicated in this disease. Many hypertensive stimuli have triggering effects on
the central nervous system and signals arising from the circumventricular organ seem to
promote inﬂammation. Studies have suggested that central signals activate macrophages
andT cells, which home to the kidney and vasculature and release cytokines, including IL-6
and IL-17, which in turn cause renal and vascular dysfunction and lead to blood pressure ele-
vation.These recent discoveries provide a new understanding of hypertension and provide
novel therapeutic opportunities for treatment of this serious disease.
Keywords: blood pressure, macrophages, interleukin 17, interleukin 6, superoxide, sympathetic nerves, T cells,
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INTRODUCTION
Hypertension is an enormous clinical burden in Western Soci-
eties and represents a major risk factor for stroke, myocar-
dial infarction, and heart failure. One third of the popula-
tion is hypertensive, while another third has “pre-hypertension”
and commonly develop overt hypertension in 2 years (Lenfant
et al., 2003; Julius et al., 2006; Narayan et al., 2010). By age
70, 70% of United States citizens have hypertension. Despite
the frequency of this disease, its cause in the majority of adults
is unknown. In virtually all cases of adult hypertension, sys-
temic vascular resistance is increased, suggesting a vascular cause
of the disease. In keeping with this, vasodilator agents such
as calcium channel antagonists and hydralazine lower blood
pressure in many instances. In addition, the kidney is often
implicated in hypertension. Most inherited single gene defects
that cause hypertension affect the distal nephron, leading to
sodium and volume retention (Lifton et al., 2001). Finally, there
is ample evidence that the central nervous system is altered
in hypertension. Central administration of angiotensin II pro-
motes neuronal ﬁring in speciﬁc centers including the subfornical
organ and this increases sympathetic outﬂow, thereby increas-
ing systemic blood pressure (Scroop and Lowe, 1968; Peter-
son et al., 2006). Increased renal sympathetic nerve trafﬁc pro-
motes hypertension, and renal sympathectomy lowers blood pres-
sure in both experimental animals and humans (Dibona and
Esler, 2010; Esler et al., 2010). The precise mechanisms whereby
these various systems interact to cause hypertension remain
unclear.
THE ROLE OF IMMUNITY AND INFLAMMATION IN
HYPERTENSION – HISTORICAL PERSPECTIVES
For almost half a century there has been evidence that the immune
system is involved in hypertension. Inﬂammatory cells, including
T cells and macrophages, have been observed in the kidneys of
hypertensive animals and humans and have been implicated in
renal damage. In the past decade, new methodology and experi-
mental models for study of adaptive and innate immunity have
been developed that have led to a new understanding of this com-
plex disease. This new information will be covered in this review
and a proposal for the role of inﬂammation in hypertension will
be discussed.
SITE OF INFLAMMATION IN HYPERTENSION
As reﬂected above, organs most often implicated in hypertension
are the vasculature, the kidney, and the brain. Inﬂammatory cells
accumulate in all of these organs in the setting of hypertension,
although most research to date has focused on the vasculature
and the kidney. In the blood vessel, we have found that chronic
angiotensin II infusion causes vascular accumulation of T cells,
B cells, macrophages, and to a lesser extent, dendritic cells. Of
note, these cells predominantly accumulate in the adventitia and
perivascular adipose tissue (PVAT) of the larger vessels and of
smaller resistance vessels such as the mesenteric arcade. Our pre-
liminary data indicate that the degree of PVAT inﬂammation in
hypertension is greater than in other visceral fat, and that hyper-
tensive stimuli do not promote inﬂammation in the subcutaneous
fat. The precise reason why inﬂammatory cells accumulate in the
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perivascular regions remains unclear, however sympathetic nerves
terminate in these regions, and might contribute to signaling this
inﬂammatory process. Inﬂammation in the PVAT occurs not only
in hypertension, but in other cardiovascular conditions, includ-
ing obesity and atherosclerosis (Hagita et al., 2011; Ohman et al.,
2011). PVAT releases factors that affect vascular tone and generates
chemotactic molecules that promote inﬂammation. An important
player in accumulation of leukocytes in the PVAT is P-selectin
glycoprotein ligand-1 (PSGL1), a key ligand for both P- and E-
selectins on leukocytes (Russo et al., 2010). Mice lacking this have
reduced accumulation of PVAT macrophages when crossed to a
genetically obese background and reduced rolling of leukocytes
on venular endothelium compared to animals with this ligand.
Moreover, PSGL1 deﬁcient mice have reduced serum levels of sol-
uble E and P-selectin and MCP1. Bone marrow transplant studies
have shown that this is a property of PSGL1 on the leukocytes
rather than the fat or vasculature per se. In addition, perivascular
venules likely express other chemokines that promote leukocyte
transmigration.
There is also evidence that inﬂammatory cells accumulate in
perivascular regions in the kidney, and in and around glomeruli.
Theuer et al. (2002) have shown that there is extensive perivas-
cular inﬁltration of leukocytes in the kidney and heart of double
transgenic rats harboring the human renin and angiotensinogen
genes. These investigators found that pyrrolidine dithiocarbamate
(PDTC), an antioxidant and an inhibitor of NFκB, prevented
monocyte/macrophage inﬁltration in these animals, and reduced
expression of NFκB-dependent genes, including the intracellu-
lar cellular adhesion molecule-1 (ICAM-1) and the inducible
nitric oxide synthase (iNOS). The authors also showed that PDTC
markedly enhanced survival in these rats, reduced albuminuria,
decreased cardiac hypertrophy, and reduced bloodpressure. PDTC
also reduced NFκB activation, ICAM-1, and iNOS levels in this
experimental model. This study emphasized the role of NFκB-
mediated inﬂammation in blood pressure elevation and its impor-
tance in producing end-organ damage. There is also evidence of
macrophage and T cell inﬁltration in the glomeruli of hyperten-
sive animals and humans. Chronic infusion of endothelin-1 causes
endothelial injury, podocyte damage, and enhances glomerular
leukocyte inﬁltration in rats, likely via endothelin A receptor acti-
vation (Saleh et al., 2010). In humans, Imakiire et al. (2007)
have shown that angiotensin converting enzyme inhibitors reduce
macrophage inﬁltration of the glomerulus.
While less studied, the brain is also a site of inﬂamma-
tion in hypertension. Particularly important are microglial cells,
which are the resident immune cells of the CNS. Microglia
are derived from monocytic cells and develop properties sim-
ilar to activated macrophages during inﬂammation (Ransohoff
and Perry, 2009). Recently, Shi et al. (2010) showed that chronic
angiotensin II infusion in rats activates microglial cells in the par-
aventricular nucleus (PVN), a site that integrates signals from
the forebrain and in turn sends efferent projections to the
brainstem to modulate blood pressure. The authors found that
concomitant intracerebroventricular (ICV) infusion of the anti-
inﬂammatory antibiotic minocycline not only prevents microglial
activation, but also hypertension. The authors also showed that
angiotensin II increasesmRNAexpression of the proinﬂammatory
cytokines 1L-1β, TNFα, and IL-6 and a decrease in the anti-
inﬂammatory cytokine IL-10. Minocycline reverses these per-
turbations of cytokine production. Moreover, the authors used
adenoviral gene therapy to overexpress IL-10 and found that
this prevents hypertension while ICV injection of IL-1β causes
hypertension.
Patton and co-workers have implicated brainstem inﬂamma-
tion in hypertension, demonstrating a role of junctional adhesion
molecule-1 (JAM-1) in hypertension (Waki et al., 2007). JAM-1 is
an adhesion molecule expressed at endothelial cell junctions and
involved in leukocyte binding to the endothelium. The authors
found that JAM-1 is upregulated in the brainstem of sponta-
neously hypertensive rats (SHR), and that overexpression of JAM-
1 in the nucleus tractus solitarius raises blood pressure and leads
to leukocyte adhesion in the brainstem of normal rats. This paper
emphasized a role of leukocyte/endothelial adhesion in central
nervous system in hypertension.
As in other organs, resident immune cells in the CNS are local-
ized in the perivascular space. In the CNS this specialized region
is known as the Virchow–Robin space. This pre-lymphatic space
provides a communication between the central nervous system
and the peripheral immune system (Williams et al., 2001; Marin-
Padilla and Knopman, 2011). Interestingly, studies usingmagnetic
resonance imaging have shown that hypertension increases in size
of the Virchow–Robins space in humans (Heier et al., 1989). The
Virchow–Robin space is similarly dilated in dementia and aging,
andmight reﬂect a common pathology between these diseases and
hypertension.
TYPES OF INFLAMMATORY CELLS INVOLVED IN
HYPERTENSION
MONOCYTES AND MACROPHAGES
Cells of themonocyte/macrophage line have been identiﬁed in the
kidney and the vasculature in hypertension for many years. In the
SHR, Clozel et al. (1991) found that the distribution of suben-
dothelial macrophages corresponded to endothelial function and
that treatment with an angiotensin I-enzyme converting inhibitor
improved endothelial function and reduced the number of vas-
cular macrophages. Various models of hypertension, including
angiotensin II infusion, lead-induced hypertension, and high salt
have been shown to increase renal accumulation of macrophages
(Franco et al., 2007; Rodriguez-Iturbe et al., 2008). Despite these
observational studies, to date only a few studies have attempted
to genetically or chemically modify the level of macrophages to
examine their role in hypertension. In two studies, Schiffrin and
co-workers examined hypertension in Op/Op mice, which have a
deﬁciency of macrophage colony stimulating factor and reduced
monocytes and macrophages (De Ciuceis et al., 2005; Ko et al.,
2007). These mice were found to develop less vascular remod-
eling, endothelial dysfunction, and vascular oxidative stress as
compared to wild-type mice in response to either angiotensin II
or DOCA–salt challenge.
RecentlyWenzel et al. employed an elegant approach to deplete
macrophages in mice to examine their role in hypertension. The
investigators used Cre–Lox technology to induce expression of the
diphtheria toxin receptor in LysM positive cells, leading to deple-
tion of neutrophils and macrophages in these animals (Wenzel
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et al., 2011). This genetic manipulation markedly blunted virtu-
ally all consequences of angiotensin II infusion, including blood
pressure elevation, the induction of vascular adhesion molecules,
vascular dysfunction, and superoxide production.
While the studies by Wenzel et al. (2011) and Schiffrin and
co-workers have shown that macrophages play an essential role
in hypertension, the precise mechanisms by which this occurs
remain unclear. In all of these studies, elimination of macrophages
reduced vascular oxidative stress, improved vascular function and
reduced the deleterious vascular remodeling that accompanies
hypertensive stimuli. A simple interpretation of these studies is
that macrophages are powerful sources of ROS, which under-
lie all of these phenomena. It is also possible that products of
macrophages, including ROS and cytokines, diffuse to the adja-
cent endothelial cells and vascular smooth muscle cells to alter
function of these cells. This could include activation of ROS gen-
erating enzymes in these adjacent cells, stimulation of vascular
smooth muscle hypertrophy and growth, promotion of vascu-
lar chemokines, cytokines and adhesion molecules, alterations of
NO production, and other alterations of vascular cell signaling.
Similar actions of ROS and cytokines on renal epithelial cells
could also promote sodium and volume retention. These phe-
nomena likely interact to promote hypertension. Finally, is likely
that the genetic manipulations in the studies by Wenzel et al.
and Schiffrin and co-workers could affect at least some popula-
tions of dendritic cells, which in addition to macrophages can
present antigens involved in T cell activation, which is important
in the genesis of hypertension. This is discussed in later in this
review.
In addition to a deleterious role in hypertension, some sub-
sets of macrophages are likely protective. Recently, Machnik et al.
(2009) showed that salt loading increases macrophage accumula-
tion in the subcutaneous space and that these are stimulated by
the hypertonic environment in this site to produce the vascular
endothelial growth factor C (VEGF-C). This leads to exuberant
proliferation of subcutaneous lymphatics. This response is pro-
tective, because clodronate-mediated depletion of macrophages
prevents the lymphatic proliferation and leads to hypertension in
response to salt loading.
T LYMPHOCYTES
It is rather easy to understand why macrophages participate in
the inﬂammatory response in hypertension. Macrophages are
components of the innate immune system, and are poised to
respond to non-speciﬁc stimuli, such as might be present in
the tissue damage induced by angiotensin II, salt, or elevated
pressure. Much more surprising is the concept that the adap-
tive immune response is involved in the genesis of hypertension.
This idea is not new, but has been established in the literature
for almost half a century. Studies by Grollman and co-workers
showed that immunosuppressive therapy targeted toward adap-
tive immunity attenuates experimental hypertension caused by
partial renal infarction (White and Grollman, 1964). The investi-
gators found anti-kidney antibodies in these animals, and showed
that transfer of lymph node cells from rats with renal infarction
to normal rats increases blood pressure in the recipients (Okuda
and Grollman, 1967). Ba et al. (1982) found that engraftment
of normal thymus into SHR restores T cell function and low-
ers blood pressure. Bendich et al. (1981) found that treatment
with anti-thymocyte serum lowers blood pressure in this model of
spontaneous hypertension. The immunosuppressant cyclophos-
phamide also transiently lowers blood pressure in SHR (Dzielak,
1991).Moreover, inmineralocorticoid-induced hypertension, sev-
eral early studies showed that T cells are also important. Immune
deﬁcient mice do not sustain this form of hypertension (Svend-
sen, 1976), and transfer of splenocytes from rats with DOCA–salt
hypertension raises blood pressure in recipient rats (Olsen, 1980).
More recently we have found that RAG-1−/− mice, which lack
T and B cells, are resistant to the development of hypertension
in response to either chronic angiotensin II infusion, DOCA–salt
challenge, or norepinephrine. Adoptive transfer of T cells, but not
B cells, restores hypertension to these various challenges (Guzik
et al., 2007;Marvar et al., 2010). These studies have been replicated
in mice with severe combined immunodeﬁciency (Crowley et al.,
2010). Transfer of CD4+ cells from rats with pregnancy-related
hypertension (pre-eclampsia) to normal pregnant rats increases
blood pressure in the recipient rats (Wallace et al., 2011). Taken
together, these studies demonstrate that T cells are essential for
development of many types of experimental hypertension, despite
the underlying stimulus.
We have also performed several studies to understand how
the central nervous system contributes to T cell activation in
hypertension. It is well known that the central nervous system
communicates with the immune system and plays a role in the
activation of immune cells (Oke and Tracey, 2009). The spleen
and lymph nodes receive sympathetic innervation and possess
adrenergic receptors which modulate their activation, antigen
presentation, and cytokine production in diverse ways (Marvar
et al., 2011). We have performed several studies showing that cen-
tral stimuli are upstream of T cell activation in hypertension. To
address this question we produced lesions anterior and ventral to
the 3rd ventricle (AV3V lesions) of mice. Lesions at this site disrupt
signals from the subfornical organ to the hypothalamus and are
known to prevent most forms of experimental hypertension. We
found that AV3V lesions reduce blood pressure elevation and pre-
vent T cell activation in response to angiotensin II (Marvar et al.,
2010). Moreover, AV3V lesions prevent the vascular accumulation
of leukocytes, composed largely of T cells and macrophages, in
response to angiotensin II. This is a speciﬁc response to the AV3V
lesioning, because norepinephrine infusion, which bypasses the
effect of AV3V lesions, causes hypertension, and T cell activation
after such lesions. In other studies, we increased central signal-
ing using two approaches. In the ﬁrst, we deleted the extracellular
superoxide dismutase (ecSOD or SOD3) in the circumventricular
organs (CVO)ofmice usingCre–Lox technology (Lob et al., 2010).
This increases oxidative stress in these sites, particularly in the
subfornical organ, which in turn increases sympathetic outﬂow,
causes amodest elevation in baseline blood pressure andmarkedly
increases the hypertension caused by a low-dose of angiotensin II.
Moreover, T cell activation is markedly enhanced in mice with
SOD3 deleted in the CVO in response to this normally subpres-
sor dose of angiotensin II. These studies clearly demonstrate an
important link between central modulation of blood pressure and
peripheral immune activation in the genesis of hypertension.
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We have also examined the role of T cells in the blood pres-
sure response to chronic psychological stress (Marvar et al., 2012).
In these studies, repeated daily cage switch and restraint stress
produced modest hypertension in normal mice, but not in RAG-
1−/− mice. Adoptive transfer of T cells to RAG-1−/− mice restores
the hypertensive response to chronic stress. Moreover in nor-
mal mice, chronic stress causes activation of circulating T cells
and increases vascular accumulation of T cells. These effects are
markedly enhanced by infusion of angiotensin II. These stud-
ies provide a link between chronic emotional stress, inﬂamma-
tion, and hypertension commonly reported in the epidemiologic
literature.
In many immune responses, T regulatory (Tregs) cells provide
a brake to the inﬂammatory process, and recent evidence suggests
that is true for hypertension. These are a distinct subset of CD4+
cells characterized by expression of the forkhead transcription fac-
tor FOXP3 and the surfacemarker CD25, and have a critical role in
self-tolerance (Sakaguchi et al., 2006). Genetic deletion of FoxP3
leads to a loss of Tregs and a severe, fatal lympho-proliferative dis-
order (Fontenot et al., 2003). In a recent study,Kvakan et al. (2009)
showed that adoptive transfer of Tregs does not affect blood pres-
sure elevation, but reduces cardiac inﬂammation, hypertrophy,
and ﬁbrosis caused by chronic angiotensin II infusion and high
salt feeding. Treg adoptive transfer also reduces the percent of cir-
culating T cells that express markers of activation and improved
electrical stability. Three recent studies have shown that adoptive
transfer of Tregs cells, but not T effector T cells, reduces hyperten-
sion caused by either angiotensin II or aldosterone (Barhoumi
et al., 2011; Matrougui et al., 2011; Kasal et al., 2012). In the
most recent of these, angiotensin II infusion was found to cause
a decrease in splenic Tregs cells and to stimulate apoptosis of Tregs
when administered in culture. The authors also found evidence of
macrophage activation in hypertensive mice, and that adoptive
transfer of Tregs reduced this. Interestingly, coronary endothe-
lial function is impaired in angiotensin II-treated mice, and Treg
adoptive transfer ameliorates this (Matrougui et al., 2011).
Additional information regarding the role of Tregs in hyper-
tension comes from studies by Viel et al. (2010) who studied rats
harboring the Dahl salt-sensitive (SS) genome with a substitu-
tion of chromosome 2 of the Brown Norway normotensive strain
(SSBN2 rats). This chromosome has quantitative trait loci for
hypertension and contains genes associated with both hyperten-
sion and inﬂammation. The authors found that these SSBN2 rats
have reduced hypertension, less vascular hypertrophy, and reduced
aortic inﬂammation compared toDahl SS rats. The SSBN2 rats also
have more aortic Tregs as evidenced by increased FoxP3b mRNA.
The anti-inﬂammatory cytokine IL-10 both induces and is pro-
duced by Treg cells. The genetic substitution in the SSBN2 rats led
to increased IL-10 production by Tregs compared to Tregs of the
Dahl SS rats. These data indicate that Tregs could mitigate both
blood pressure elevation and end-organ damage in the SSBN2
animals. In keeping with a protective role of IL-10, Didion and
co-workers found that carotid arteries of IL-10−/− mice develop
marked endothelial dysfunction when incubated with angiotensin
II, while arteries of wild-type mice are resistant to this insult.
Likewise, angiotensin II increases vascular superoxide in IL-10−/−
mice, but not in wild-type animals (Didion et al., 2009).
These studies support the concept that Tregs cells modulate
hypertension and the end-organ damage caused by stimuli such
as high salt, angiotensin II, and aldosterone. This is compatible
with the known role of these cells to modulate other immune
responses. It is unclear if hypertensive stimuli might also lead to
Tregs cell dysfunction or alter homing of these cells to areas of
inﬂammation.
ANTIGEN PRESENTING CELLS
If T cells are important in hypertension, it follows that an anti-
gen or series of antigens must be involved. It is reasonably likely
that these are modiﬁcations of endogenous proteins, or so-called
neoantigens, that occur in response to the stimuli leading to
hypertension. Because of the known role of oxidative injury in
hypertension, it is possible that these neoantigens are oxidatively
modiﬁed proteins, however their identity remains unknown. The
most efﬁcient professional antigen presenting cells (APCs) are
dendritic cells, but macrophages and B lymphocytes also present
antigen. Little is known regarding the role of APCs in hyperten-
sion. APCs not only present antigen to the T cell receptor, but also
co-stimulatory factors. Among themost important of these are the
B7 ligands, which include CD80 and CD86. The B7 ligands engage
CD28 on T cells during T cell receptor activation, and these two
signals coordinate T cell activation. In the absence of adequate co-
stimulation, T cells are either incompletely stimulated or undergo
apoptosis. Recently,wehaveprovided evidence that co-stimulation
by APCs plays an important role in hypertension (Vinh et al.,
2010).We found that the pharmacological agent Abatacept, which
blocks the CD28/B7 interaction, prevents both angiotensin II and
DOCA–salt hypertension. Moreover, the hypertension caused by
angiotensin II is markedly reduced in mice lacking B7 ligands,
and can be restored by bone marrow transplant with wild-type
marrow. In this study, we also found that an increase in activated
dendritic cells in the spleen and lymphnodes in hypertensivemice.
Dendritic cell activation occurs during antigen uptake and presen-
tation, and thus our ﬁndings suggest that dendritic cells likely are
actively involved in uptake and presentation of neoantigens to T
cells in hypertension.
THE MECHANISMS BY WHICH INFLAMMATORY CELLS
PROMOTE HYPERTENSION
While the above studies strongly support a role of inﬂamma-
tory cells in hypertension, the precise mechanisms involved in
this process remain a focus of substantial research. In the case
of T cells, various hypertensive stimuli increase the percent of
circulating T cells with an effector phenotype. These cells accu-
mulate in the PVAT and in the kidney where they release cytokines
that seem to have a critical role in raising blood pressure. A par-
ticularly important cytokine seems to be interleukin-17 (IL-17).
TH17 cells, a unique subset of CD4+ cells, distinct from TH1 and
TH2 cells, were initially thought to be the major source of this
cytokine. It is now recognized that IL-17 is also made by CD8+
cells (Kondo et al., 2009), neutrophils (Li et al., 2010), and nat-
ural killer T cells (Lee et al., 2008). IL-17 contributes to a variety
of human diseases including rheumatoid arthritis, inﬂammatory
bowel disease, psoriasis, and airway inﬂammation (Witowski et al.,
2004). We found mice lacking IL-17A (IL-17−/− mice) develop
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blunted hypertension during angiotensin II infusion and that the
increase in superoxide production and reduction of endothelium-
dependent vasodilatation observed in hypertensivewild-typemice
does not occur in IL-17−/− mice (Madhur et al., 2010). In keep-
ing with this, it has recently been reported that IL-17 can activate
the NADPH oxidase, a major source of reactive oxygen species in
hypertension (Pietrowski et al., 2011). We also found that the vas-
cular accumulation of leukocytes (including other T cells) caused
by angiotensin II is markedly reduced in IL-17−/− mice. This is in
accord with the concept that IL-17 stimulates chemokine release
and promotes chemotaxis of other inﬂammatory cells (Kao et al.,
2005; Hartupee et al., 2007). Thus, IL-17 likely contributes to vas-
cular pathology in hypertension not only by direct effects, but also
by recruiting other inﬂammatory cells.
Of interest, amajor driver of IL-17 expression is IL-6,which acts
in concert with transforming growth factor to polarize both CD4+
andCD8+ cells toward IL-17 production. IL-6 is amultifunctional
cytokine produced by many cells including T cells, B cells, ﬁbrob-
lasts, and endothelial cells. In vivo treatment with IL-6 causes fever,
weight loss, and generalized fatigue. IL-6 stimulates the liver to
produce acute phase reactants including serum amyloid A and
C-reactive protein and to decrease production of albumin (Nishi-
moto, 2010). Antibodies to IL-6 have been used to treat a variety of
human diseases, including rheumatoid arthritis, Crohn’s disease,
lupus erythematosus, Casteleman’s disease, Stills disease, systemic
onset juvenile onset arthritis (soJIA), and a variety of neoplasms.
Both clinical observations and experimental studies have strongly
implicated IL-6 in the genesis of hypertension. In the early 1990s,
it was recognized that some pheochromocytomas, which cause
severe hypertension, produce IL-6 (Suzuki et al., 1991). There are
signiﬁcant, albeit weak correlations between serum IL-6 levels and
blood pressure in healthy volunteers (Chae et al., 2001; Fernandez-
Real et al., 2001), and lowering blood pressure reduces serum IL-6
levels in hypertensive subjects (Vazquez-Oliva et al., 2005). A very
recent study has shown that IL-6 accumulates in the kidney, and
in particular the glomeruli, of patients with chronic kidney dis-
ease and hypertension, to a greater extent than in patients with
CKD and no hypertension (Zhang et al., 2012). In Wystar-Kyoto
rats, renal sympathetic nerve stimulation increases renal produc-
tion of IL-6 (Nakamura et al., 1993). Angiotensin II stimulates the
production of IL-6 by vascular smooth muscle cells via a pathway
involving the AT1 receptor, increased intracellular calcium, tyro-
sine kinase and MAP kinase stimulation and IL-6 transcriptional
activation (Funakoshi et al., 1999). Several studies have shown that
IL-6 deﬁcient mice are protected against stress-induced hyper-
tension, angiotensin II-induced hypertension, and renal damage
caused by hypertension (Lee et al., 2004; Hartupee et al., 2007;
Sturgis et al., 2009; Brands et al., 2010; Zhang et al., 2012). In an
elegant study, Luther et al. (2006) showed that acute angiotensin
II infusion in humans increases circulating IL-6, and that this is
prevented by pretreatment with spironolactone, indicating a role
of aldosterone in this response.
Based on these studies, it has become clear that inﬂamma-
tory cytokines such as IL-17 and IL-6 contribute to hypertension,
likely both by worsening blood pressure elevation and by causing
end-organ damage. Studies such as these have led to the proposal
that IL-6 antagonists could be used to treat resistant hypertension
(Kapoor, 2007). The precise mechanisms by which these cytokines
interact remains unclear, but it is interesting to speculate that IL-6
production in the kidney or vasculature might induce T cells to
produce IL-17, ultimately leading to hypertension.
SUMMARY – AN INTEGRAL ROLE OF INFLAMMATION IN THE
SYSTEMS BIOLOGY VIEW OF HYPERTENSION
As mentioned in the introduction of this chapter, there remains
substantial debate about the precise roles of the central nervous
system, the kidney, and the vasculature in hypertension and a
clear understanding of how a stimulus like angiotensin II can
coordinate dysfunction of all of these remains undeﬁned. We
propose that inﬂammation provides a link between these sys-
tems, and by producing dysfunction in each, leads to an eleva-
tion of blood pressure. This working hypothesis is pictured in
Figure 1. Stimuli such as angiotensin II, high salt, or chronic
stress activates regions of the brain such as the CVO, leading to
an increase in sympathetic outﬂow and perhaps other signals that
cause modest elevations in systemic pressure (pre-hypertension)
and promote local production of cytokines. The elevations in
pressure, in concert with the direct insults of angiotensin II
and increased neurotransmitters such as norepinephrine lead
to tissue injury, release of tissue-derived cytokines such as IL-6
and formation of neoantigens, perhaps due to oxidative mod-
iﬁcations. APCs, including dendritic cells and macrophages are
involved in presenting these neoantigens, leading to T cell acti-
vation. The activated T cells produce cytokines such as IL-17,
which are critical in the hypertensive process. This inﬂamma-
torymilieu, comprised of IL-17, IL-6, catecholamines, angiotensin
II, and ROS promote sodium retention in the kidney and in
the vasculature causes vasoconstriction and vascular remodeling.
These events cause progression of pre-hypertension to overt severe
hypertension.
It is interesting to note that there is a consistent theme of inter-
play between oxidative events and inﬂammation in this pathway.
An initial step involves activation of CNS centers including the
CVO. This leads to an inﬂammatory response in the hypothala-
mus, characterized by activation of microglia,which alters input to
brainstem cardiovascular centers and promotes sympathetic out-
ﬂow.Mechanical deformation of vascular cells promotes a cascade
of signaling and transcriptional events that stimulate expression
of adhesion molecules and chemokines necessary for leukocyte
trafﬁcking. Formation of neoantigens, perhaps due to oxidative
modiﬁcationsmight lead toT cell activation. The ultimate increase
in vascular superoxide is clearly T cell dependent, and is absent
in RAG-1−/− mice and mice lacking IL-17A. Paradoxically, small
clinical trials have failed to show a long-term beneﬁt of commonly
employed vitamin antioxidants in hypertension (Kim et al., 2002;
Ward et al., 2007). These clinical studies might reﬂect the fact
that ROS can also have beneﬁcial effects, that scavenging all ROS
might be deleterious and that these commonly employed agents
are simply not very effective when administered in vivo (Widder
and Harrison, 2005).
Finally, the studies described abovehave largely beenperformed
in the early phases of hypertension in experimental animals. It is
unclear if inﬂammation and immune cells contribute to estab-
lished, long-standing human hypertension. Moreover, commonly
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FIGURE 1 | Proposed paradigm for inflammation and immune cell
activation in hypertension. Stimuli including angiotensin II, salt, and chronic
stress act on the central nervous system and increase sympathetic outﬂow.
The circumventricular organs (CVO), including the subfornical organ (SFO), the
medium preoptic eminence (MPO, orange structure) organum vasculosum
lateral terminalis (OVLT, yellow structure), and the area postrema (AP) have a
poorly formed blood–brain barrier and are responsive to circulating
angiotensin II and sodium. These stimuli increase ROS production in the CVO,
which provide input into hypothalamic centers including the paraventricular
nucleus (PVN). Microglial cells are activated in this process, and increase
input into brainstem centers including the ventral lateral medulla (VLM) and
the nucleus tractus solitarius (NTS). These increase sympathetic outﬂow,
which causes a modest elevation in blood pressure to levels compatible with
pre-hypertension. Sympathetic stimulation also increases renal production of
IL-6 and acts onT cell adrenergic receptors to modify their polarization. The
elevations of pressure, direct actions and angiotensin II and catecholamines
activate ROS production in the kidney and vasculature, increasing chemokine
production and adhesion molecule expression.We propose that neoantigens
(nAg) are formed from endogenous proteins in the kidney and vasculature,
which are presented by dendritic cells to T cells. ActivatedT cells interact with
monocyte/macrophages, promoting macrophage transformation and these
leukocytes accumulate in the kidney. IL-6 andTGFβ, produced in these organs,
help direct T cell IL-17 production. IL-17 and other cytokines produced by these
cells promote ROS production in the vascular smooth muscle and kidney,
leading to vasoconstriction, sodium retention, and ultimately severe
hypertension.
employed anti-inﬂammatory drugs, including cyclosporine and
non-steroidal inﬂammatory drugs (NSAIDs) have off target effects
that promote, rather than prevent hypertension. Cyclosporine
increases sympathetic outﬂow and endothelin expression in the
kidney (Kon et al., 1990; Scherrer et al., 1990; Zhang et al., 2000),
while NSAIDs inhibit production of vasodilator and natriuretic
prostaglandins that could promote hypertension (Morrison et al.,
2007). It is conceivable that agents that speciﬁcally interfere with
T cell activation without off target effects could be used to treat
refractory hypertension in humans, however additional studies are
needed to address this issue.
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